1stOncology™: Cancer Intelligence Service – Page 5895 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Precision BioSciences to Participate in Upcoming H.C. Wainwright Cell Therapy Virtual Conference

On February 22, 2023 Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, reported that the Company will participate in the H.C. Wainwright Cell Therapy Virtual Conference taking place February 28, 2023 Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, reported that the Company will participate in the H.C. Wainwright Cell Therapy Virtual Conference taking place February 28, 2023.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Details for the virtual fireside chat are as follows:
Date: Tuesday, February 28, 2023
Time: 2:00 PM ET

The fireside chat will be available via a live webcast accessible on Precision’s website in the Investors section under Events & Presentations on February 28, 2023: View Source An archived replay will be available for approximately 30 days following the event..

Details for the virtual fireside chat are as follows:
Date: Tuesday, February 28, 2023
Time: 2:00 PM ET

Phio Pharmaceuticals Appoints Robert Bitterman as President and Chief Executive Officer

On February 22, 2023 Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL RNAi platform technology is designed to make immune cells more effective in killing tumor cells, reported that Robert Bitterman has been appointed by the Board of Directors to serve as the Company’s President and Chief Executive Officer, effective as of February 20, 2023 (Press release, Phio Pharmaceuticals, FEB 22, 2023, View Source [SID1234627523]). Mr. Bitterman has served as Interim Chief Executive Officer since September 2022. Mr. Bitterman will continue to serve as Chair of the Board, and as the Company’s principal executive officer and principal financial officer.

Logo – View Source

"As we considered the next chapter for Phio, the Board undertook a thorough search for a full-time CEO," said Robert Ferrara, Phio’s Lead Independent Director. "We evaluated potential candidates who could effectively lead the Company at this important time in its history, as we ramp up our clinical activities and manage several development programs with our partners. Since taking on the interim CEO role in September 2022, Bob has proven to be a strategic and effective leader of Phio. His extensive leadership experience and existing knowledge of our pipeline make him the most qualified executive to lead Phio forward as we advance our clinical programs and drive shareholder growth. We appreciate his stepping into this role full-time."

"During the last several months, I have seen the passion and dedication of Phio’s team as we continue to make steady progress across several programs in our pipeline and set a clear path for the future. I look forward to continuing to advance our strategy and delivering on several of the preclinical and clinical milestones set for 2023 and 2024," stated Mr. Bitterman.

Mr. Bitterman has served as a member and the Chairman of the Company’s Board since 2012 and as the Interim Executive Chairman of the Company since September 2022. Previously, Mr. Bitterman served as the President and Chief Executive Officer of Cutanea Life Sciences, Inc., a private company he founded in 2005 that focused on developing innovative technologies to treat diseases and disorders of the skin and subcutaneous tissue. He led the company until its acquisition by Biofrontera, Inc., USA in March 2019. Prior to his role at Cutanea Life Sciences, Inc., Mr. Bitterman held the position of President and Chief Executive Officer of Isolagen, Inc., President and General Manager of Dermik Laboratories, and various positions of increasing responsibility in financial and commercial capacities within Aventis S.A. Mr. Bitterman holds an A.B. degree in Economics from The College of the Holy Cross, and a Master of Business Administration degree from Boston University. He also holds a Doctor of Humane Letters (Honoris Causa) from the New York College of Podiatric Medicine.

Nykode Therapeutics to announce financial results for the fourth quarter 2022 and host webcast presentation on February 28, 2023

On February 22, 2023 – Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, reported it will report its financial results for the fourth quarter of 2022 on Tuesday, February 28, 2023, before market open and subsequently host a webcast presentation at 4 p.m. CET / 10 a.m. ET (Press release, Nykode Therapeutics, FEB 22, 2023, View Source [SID1234627522]).

A live and archived webcast of the presentation can be accessed in the Investors section of the Company’s website: View Source

Lineage Enters Into Option and License Agreement With Eterna Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications

On February 22, 2023 Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies to replace and restore specific cell types of the human body, reported that it has entered into an exclusive option and license agreement (the "Agreement") with Eterna Therapeutics Inc. ("Eterna") for the development of novel beta 2 microglobulin (B2M)-deficient induced pluripotent stem cell (iPSC) lines, which Lineage will evaluate for development into differentiated cell transplant therapies (Press release, Lineage Cell Therapeutics, FEB 22, 2023, View Source [SID1234627521]). The new cell lines to be developed by Eterna will support the potential creation of additional product candidates at Lineage, specifically for the treatment of certain central nervous system (CNS) disorders and other neurology indications. Eterna is the exclusive licensee of the key intellectual property underlying this collaboration from its discovery partner Factor Bioscience.

This press release features multimedia. View the full release here: View Source

"This agreement provides the opportunity to combine insights obtained from our dry age-related macular degeneration program with new tools, to broaden the scope of our technology and may help deliver solutions for a wider range of diseases. The engineering of desirable properties into cell lines can also lead to treatments that are highly differentiated from our competitors," stated Brian M. Culley, Lineage’s CEO. "The initial cell lines we envision bringing into the clinic through this agreement will utilize proprietary mRNA-based gene-editing technology developed by Eterna’s CEO, Dr. Matt Angel. It is natural that we would look to introduce aspects of gene editing, hypoimmunity, and additional pluripotent cell lines alongside our existing directed differentiation capabilities in the furtherance of our overall goal of becoming a comprehensive leader in cell therapy."

Under the Agreement, Eterna plans to conduct certain gene-editing activities and provide materials to Lineage for evaluation. The Agreement provides Lineage an option to obtain an exclusive license to utilize and sublicense the novel gene-edited cell lines for preclinical, clinical, and commercial purposes in the field of CNS diseases. A feature of the starting cell line is the targeted deletion of the B2M gene, which is designed to reduce the immunogenicity of product candidates derived from the lines by inhibiting rejection by CD8+ T cells. Lineage expects this attribute will expand the edited cell lines’ overall utility, including for non-immune privileged or non-human leukocyte antigen (HLA) matched indications. Additional planned gene edits may further differentiate the cell line from others currently in use by competitors. Financial terms were not disclosed.

"The cell therapy expertise demonstrated by Lineage makes them an attractive partner to deploy our mRNA cell engineering platform for the generation of novel gene-edited iPSC lines for neurological applications," said Matt Angel, Ph.D., CEO of Eterna. "At Eterna, we have expertise in creating gene-edited iPSC lines using our extensively patented mRNA cell engineering technologies. We look forward to collaborating with the Lineage team on this project and working with them to develop these powerful tools for the generation of new, intelligently-engineered cell therapy product candidates in the CNS space."

Isofol Medical AB (publ) publishes year-end report, January – December 2022

On February 22, 2023 Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), reported that the company’s year-end report for January – December 2022 is now available on the company’s website, www.isofolmedical.com (Press release, Isofol Medical, FEB 22, 2023, View Source [SID1234627519]).

The information in the press release is intended for investors.

Fourth quarter, October – December 2022
Net revenue amounted to TSEK 1,857 (4,704) and other revenue to TSEK 57 (0)
The result for the period amounted to TSEK -25,335 (-61,170)
Earnings per share amounted to SEK -0.16 (-0.38)
Cash and cash equivalents on December 31 amounted to TSEK 190,583 (379,448)
January – December 2022
Net revenue amounted to TSEK 12,797 TSEK (22,407) and other revenue to TSEK 59 (0)
The result for the period amounted to TSEK -159,755 (-200,251)
Earnings per share amounted to SEK -0.99 (-1.59)
The Board of Directors proposes that no dividend will be paid for the 2022 financial year
Significant events during the fourth quarter 2022
On November 3 Isofol appointed its nomination committee ahead of the Annual General Meeting 2023 in accordance with the principles adopted at the Annual General Meeting on May 19, 2022.
On November 25 Isofol announced that the analysis of the AGENT study’s final data confirmed the negative topline results that were presented in August 2022. In addition, no predictive biomarkers for gene expression were identified for clinical response.
On November 28 Isofol announced that CEO Dr. Ulf Jungnelius MD would step down on June 1, 2023.
On December 21 Isofol announced that CFO and deputy CEO Gustaf Albèrt would leave the company during 2023.
Significant events after the event of the period
An extraordinary general meeting was held on February 13, 2023 to, in accordance with the board’s proposal, decide on an extra dividend and voluntary liquidation. However, the board’s proposal failed to reach the required voting majority and the resolution was therefore not adopted. As a consequence of the decision all members of the board of directors makes their postitions available and will not stand for re-election.
A written request for convening an extraordinary general meeting was received in January 2023 from shareholders with a total shareholding corresponding to more than 10 percent of the shares in the company to elect a new board. Notice of the extraordinary general meeting was sent out on February 3, 2023, and will be held on February 28, 2023.
CEO comment:
"During the quarter, we received final data that confirmed previous topline results, implicating that the objectives set together with the regulatory authorities for a market application for a new drug were not reached. In parallel, efforts to complete the closure of the AGENT study and measures to reduce costs have continued with high intensity. During January, the board proposed the company to be liquidated, however the proposal did not achieve the required majority. Given this, Isofol’s future will be decided in the first quarter of 2023," says CEO Ulf Jungnelius.

For more information, please contact
Isofol Medical AB (publ)
Ulf Jungnelius, M.D., CEO
E-mail: [email protected]
Telephone: +46 709-16 89 55

Gustaf Albèrt, CFO
E-mail: [email protected]
Telephone: +46 709-16 83 02

The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CET, on February 22, 2023.